Inventor · disambiguated record
Claudio Sturino
Also filed as: STURINO CLAUDIO · STURINO CLAUDIO F
25 granted patents·21 pending applications·246 citations·filing 2001–2025
95Inventor score
Files withGENENTECH INC10VERTEX PHARMA9MERCK FROSST CANADA INC5BERTHELETTE CARL4LIMINAL BIOSCIENCES LTD3
Top patents by PatentIndex Score
46 records- 0195US8349839B2Inhibitors of HIV replicationBOEHRINGER INGELHEIM INT·Filed 2010·Granted Jan 8, 2013·43 cites·14 claims
- 0291US6410583B1Cyclopentanoindoles, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA INC·Filed 2001·Granted Jun 25, 2002·63 cites·15 claims
- 0388US7622501B2Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST CANADA INC·Filed 2005·Granted Nov 24, 2009·14 cites·15 claims
- 0488US7622502B2Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST CANADA INC·Filed 2005·Granted Nov 24, 2009·14 cites·15 claims
- 0587US10710994B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2019·Granted Jul 14, 2020·3 cites·38 claims
- 0687US7199154B2Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST COMPANY·Filed 2003·Granted Apr 3, 2007·42 cites·18 claims
- 0787US7169809B2Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST COMPANY·Filed 2004·Granted Jan 30, 2007·35 cites·24 claims
- 0882US12281102B2Inhibitors of APOL1 and methods of using sameVERTEX PHARMA·Filed 2021·Granted Apr 22, 2025·1 cites·38 claims
- 0982US12116343B2Inhibitors of APOL1 and methods of using sameVERTEX PHARMA·Filed 2021·Granted Oct 15, 2024·1 cites·33 claims
- 1082US7618994B2Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA LTD·Filed 2007·Granted Nov 17, 2009·3 cites·23 claims
- 1182US2025122184A1Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2024·Application pending·0 cites
- 1281US6436965B1PDE IV inhibiting amides, compositions and methods of treatmentMERCK FROSST CANADA INC·Filed 2001·Granted Aug 20, 2002·17 cites·17 claims
- 1377US12202824B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2022·Granted Jan 21, 2025·0 cites·17 claims
- 1477US7317036B2Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA INC·Filed 2003·Granted Jan 8, 2008·6 cites·6 claims
- 1574US8003661B2Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonistsMERCK CANADA INC·Filed 2008·Granted Aug 23, 2011·2 cites·14 claims
- 1674US2025179091A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1771US10457654B2Therapeutic compounds and methods of use thereofGENENTECH INC·Filed 2017·Granted Oct 29, 2019·1 cites·19 claims
- 1870US9708332B2Respiratory syncytial virus inhibitorsMEDIVIR AB·Filed 2013·Granted Jul 18, 2017·1 cites·15 claims
- 1968US11655245B2Oxadiazole transient receptor potential channel inhibitorsGENENTECH INC·Filed 2020·Granted May 23, 2023·0 cites·48 claims
- 2068US11028075B2Therapeutic compounds and methods of use thereofGENENTECH INC·Filed 2019·Granted Jun 8, 2021·0 cites·10 claims
- 2167US2010081696A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2009·Application pending·0 cites
- 2264US12269831B2Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Granted Apr 8, 2025·0 cites·41 claims
- 2364US2025340543A1Gpr84 antagonists and uses thereofLIMINAL BIOSCIENCES LTD·Filed 2025·Application pending·0 cites
- 2461US2025122218A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 2559US11208387B2Macrocyclic broad spectrum antibioticsGENENTECH INC·Filed 2020·Granted Dec 28, 2021·0 cites·6 claims
- 2659US2022135528A1Macrocyclic broad spectrum antibioticsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2758US12378229B2GPR84 antagonists and uses thereofLIMINAL BIOSCIENCES LTD·Filed 2022·Granted Aug 5, 2025·0 cites·29 claims
- 2857US2006069148A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2005·Application pending·0 cites
- 2956US12324802B2Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Granted Jun 10, 2025·0 cites·53 claims
- 3056US2012115921A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2012·Application pending·0 cites
- 3155US2022081423A1Therapeutic compounds and methods of use thereofGENENTECH INC·Filed 2021·Application pending·0 cites
- 3255US2003158246A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentFiled 2003·Application pending·0 cites
- 3352US2020115354A1Therapeutic compounds and methods of use thereofGENENTECH INC·Filed 2019·Application pending·0 cites
- 3451US8685999B2Beta carboline sulphonylurea derivatives as EP4 receptor antagonistsBERTHELETTE CARL·Filed 2009·Granted Apr 1, 2014·0 cites·17 claims
- 3550US2023113202A1Gpr84 antagonists and uses thereofLIMINAL BIOSCIENCES LTD·Filed 2022·Application pending·0 cites
- 3650US2023414616A1Line-1 inhibitors to treat diseaseTRANSPOSON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3748US9399645B2Inhibitors of HIV replicationBOEHRINGER INGELHEIM INT·Filed 2012·Granted Jul 26, 2016·0 cites·8 claims
- 3848US2023115176A1Complement Modulators and Related MethodsRA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3946US2019119282A1Imidazopyridazines useful as inhibitors of the par-2 signaling pathwayVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 4045US2007054951A1Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonistsLI LIANHAI·Filed 2004·Application pending·0 cites
- 4143US2007027171A1Cycloalkanepyrrolopyridines as dp receptor antagonistsLACHANCE NICOLAS·Filed 2004·Application pending·0 cites
- 4241US10030024B2Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathwayVERTEX PHARMA·Filed 2016·Granted Jul 24, 2018·0 cites·23 claims
- 4340US2008242722A1Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular EventsDUFRESNE CLAUDE·Filed 2005·Application pending·0 cites
- 4432US2019002436A1Respiratory syncytial virus inhibitorsMEDIVIR AB·Filed 2016·Application pending·0 cites
- 4531US2018057505A1Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathwayVERTEX PHARMA·Filed 2016·Application pending·0 cites
- 4631US2001047027A1Prostaglandin D2 receptor antagonistsFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →